GT200500186A - Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits - Google Patents

Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits

Info

Publication number
GT200500186A
GT200500186A GT200500186A GT200500186A GT200500186A GT 200500186 A GT200500186 A GT 200500186A GT 200500186 A GT200500186 A GT 200500186A GT 200500186 A GT200500186 A GT 200500186A GT 200500186 A GT200500186 A GT 200500186A
Authority
GT
Guatemala
Prior art keywords
kits
receptor antagonists
progesterone receptor
contraceptive
regimes
Prior art date
Application number
GT200500186A
Other languages
English (en)
Inventor
Gary Sondermann Grubb
Ginger Dale Constantine
Andrew Fensome
Casey Cameron Mccomas
Edward George Melenski
Michael Anthony Marella
Jay Edward Wrobel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35106665&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200500186(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200500186A publication Critical patent/GT200500186A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE PROVEE UN METODO DE ANTICONCEPCION QUE INCLUYE LA ADMINISTRACION DE 21 A 27 DIAS CONSECUTIVOS DE UNO O MAS ANTAGONISTAS RP EN AUSENCIA DE UNA PROGESTINA, ESTROGENO U OTRO COMPUESTO ESTEROIDE, SEGUIDO DE 1 A 7 DIAS SIN NINGUN AGENTE ACTIVO. SE DESCRIBE, ADEMAS, UN KIT UTIL DESDE EL PUNTO DE VISTA FARMACEUTICO PARA FACILITAR LA ADMINISTRACION DE ESTE REGIMEN.
GT200500186A 2004-07-07 2005-07-04 Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits GT200500186A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58588304P 2004-07-07 2004-07-07
US67613505P 2005-04-29 2005-04-29

Publications (1)

Publication Number Publication Date
GT200500186A true GT200500186A (es) 2006-03-02

Family

ID=35106665

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200500186A GT200500186A (es) 2004-07-07 2005-07-04 Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits

Country Status (20)

Country Link
US (1) US20060009509A1 (es)
EP (1) EP1773323A1 (es)
JP (1) JP2008505906A (es)
KR (1) KR20070039912A (es)
AR (1) AR049664A1 (es)
AU (1) AU2005271974A1 (es)
BR (1) BRPI0512993A (es)
CA (1) CA2571198A1 (es)
CR (1) CR8800A (es)
EC (1) ECSP077131A (es)
GT (1) GT200500186A (es)
IL (1) IL180238A0 (es)
MX (1) MXPA06014580A (es)
NO (1) NO20070377L (es)
PA (1) PA8638501A1 (es)
PE (1) PE20060485A1 (es)
RU (1) RU2006144069A (es)
SV (1) SV2006002166A (es)
TW (1) TW200605880A (es)
WO (1) WO2006017075A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407101B1 (en) * 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6509334B1 (en) * 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
GB0121285D0 (en) * 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
EP1773344A1 (en) 2004-07-07 2007-04-18 Wyeth a Corporation of the State of Delaware Cyclic progestin regimens and kits
BRPI0513141A (pt) 2004-07-09 2008-04-29 Population Council Inc composição para anel vaginal, e, processo de contracepção a longo prazo
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
AR053710A1 (es) 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
MY158766A (en) 2005-04-11 2016-11-15 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
TW200833695A (en) 2006-10-12 2008-08-16 Xenon Pharmaceuticals Inc Use of spiro-oxindole compounds as therapeutic agents
CN105175433A (zh) 2008-10-17 2015-12-23 泽农医药公司 螺羟吲哚化合物及其作为治疗剂的用途
US8101647B2 (en) 2008-10-17 2012-01-24 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
ES2602134T3 (es) 2009-04-14 2017-02-17 Laboratoire Hra Pharma Procedimiento para anticoncepción bajo demanda
AP2012006071A0 (en) 2009-06-18 2012-02-29 Pfizer Bicyclic and tricyclic compounds as kat II inhibitors.
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
AU2010306768B2 (en) 2009-10-14 2016-08-04 Xenon Pharmaceuticals Inc. Synthetic methods for spiro-oxindole compounds
PE20121699A1 (es) 2010-02-26 2012-12-22 Xenon Pharmaceuticals Inc Composiciones farmaceuticas del compuesto espiro-oxindol para administracion topica
US9375437B2 (en) * 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
ES2524423T3 (es) 2010-12-01 2014-12-09 Pfizer Inc. Inhibidores de KAT II
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
WO2014140217A1 (en) * 2013-03-14 2014-09-18 Laboratoire Hra-Pharma Method for scheduling ovulation
US9682033B2 (en) 2015-02-05 2017-06-20 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
EP3310359A4 (en) 2015-06-22 2019-04-03 Lipocine Inc. ORAL COMPOSITIONS CONTAINING 17-HYDROXYPROGESTERONE ESTER AND METHODS RELATING THERETO

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407101B1 (en) * 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6509334B1 (en) * 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6444668B1 (en) * 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors

Also Published As

Publication number Publication date
BRPI0512993A (pt) 2008-04-22
NO20070377L (no) 2007-02-07
AU2005271974A1 (en) 2006-02-16
EP1773323A1 (en) 2007-04-18
SV2006002166A (es) 2006-05-09
RU2006144069A (ru) 2008-08-20
IL180238A0 (en) 2007-07-04
KR20070039912A (ko) 2007-04-13
JP2008505906A (ja) 2008-02-28
US20060009509A1 (en) 2006-01-12
CA2571198A1 (en) 2006-02-16
AR049664A1 (es) 2006-08-23
PE20060485A1 (es) 2006-06-24
CR8800A (es) 2007-08-28
PA8638501A1 (es) 2006-07-03
MXPA06014580A (es) 2007-03-23
WO2006017075A1 (en) 2006-02-16
TW200605880A (en) 2006-02-16
ECSP077131A (es) 2007-02-28

Similar Documents

Publication Publication Date Title
GT200500186A (es) Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits
PA8638601A1 (es) Regimenes y kits de progestina ciclica
ES2167061T3 (es) Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino.
CO2021000174A2 (es) Composiciones tópicas para el alivio del dolor
CR6210A (es) Composiciones de celecoxib
PE20060467A1 (es) Tratamiento de la hemorragia de disrupcion en regimenes anticonceptivos extendidos
BRPI0315315B8 (es)
AR074528A1 (es) Dispositivos intravaginales con un soporte rigido, metodos para su fabricacion y sus usos
ECSP088240A (es) Composición de trazodona para administración una vez por día
ATE526932T1 (de) Behälter für zu verabreichende flüssige medikamente
DE60105448D1 (de) Feste dispersionen mit nitrataktiven wirkstoffen
CL2007000345A1 (es) Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de uno o mas agentes terapeuticos y una cantidad mejoradora de la absorcion intestinal de uno o mas agonistas de receptores de zonulina/zot; y uso de la composicion para tratar la diabetes.
PA8815901A1 (es) Sistema de administracion de drogas con efecto estabilizante
BR0211365A (pt) Método e kit para inibir ou reverter o ganho de peso em um paciente sendo tratado com uma medicação antipsicótica
CR8059A (es) Composicion farmaceutica en forma de hidrogel para administracion transdermica de sustancias activas
WO2018187698A3 (en) Combination therapies using caspase-1 dependent anticancer agents and pge2 antagonists
PE20050144A1 (es) Composicion para mejorar funciones cognitivas y la memoria
BRPI0517983A (pt) uso de corticosteróide em associação com diurético e antiácido para tratamento de estenose vascular e prevenção de reestenose vascular
DE60301261D1 (de) Pharmazeutische zusammensetzungen enthaltend 17alpha-furanylester von 17beta-carbothioat androstanderivaten und einen muskarinrezeptorantagonist
CL2004001317A1 (es) Composicion farmaceutica que comprende el antagonista de receptores de progesterona 11b-(4-acetilfenil)-17b-hidroxi-17 alfa-(1,1,2,2,2-pentafluoroetil)-estra-4,9-dien-3-ona y un antiestrogeno puro; y su uso para tratar una enfermedad dependiente de h
ATE427122T1 (de) Behandlung von dermatitis mit dehydroepiandrosteron-glucocorticoid- kombinationen
UY39288A (es) Formas farmacéuticas de maleato de acalabrutinib
BRPI0510906A (pt) composição farmacêutica tópica, composição para administração tópica e seu uso
NI201900084A (es) Dropropizina en combinación con ambroxol en la forma farmacéutica de jarabe y tabletas
ECSP21001232A (es) Composición farmacéutica en la forma de un comprimido masticable de diosmina o de una fracción flavonoica